Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells
► Aromatase overexpressing and Letrozole resistant T47D cell lines were generated. ► Antiprogestin, Proellex, suppressed growth of these cells in vitro. ► Proellex action is mediated by inhibiting PR-B/p300 complex formation. ► Proellex suppresses EGFR and PR-B expression. Aromatase inhibitors (AI)...
Gespeichert in:
Veröffentlicht in: | The Journal of steroid biochemistry and molecular biology 2013-01, Vol.133, p.30-42 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 42 |
---|---|
container_issue | |
container_start_page | 30 |
container_title | The Journal of steroid biochemistry and molecular biology |
container_volume | 133 |
creator | Gupta, Akash Mehta, Rajeshwari Alimirah, Fatouma Peng, Xinjian Murillo, Genoveva Wiehle, Ronald Mehta, Rajendra G. |
description | ► Aromatase overexpressing and Letrozole resistant T47D cell lines were generated. ► Antiprogestin, Proellex, suppressed growth of these cells in vitro. ► Proellex action is mediated by inhibiting PR-B/p300 complex formation. ► Proellex suppresses EGFR and PR-B expression.
Aromatase inhibitors (AI) are considered as a first line therapy for ER+PR+ breast cancers. However, many patients acquire resistance to AI. In this study, we determined the response of antiprogestin CDB-4124 (Proellex) on the aromatase overexpressing and Letrozole resistant cell lines and also studies its mechanism of action in inhibition of breast cancer cell proliferation. For these studies we generated aromatase overexpressing T47D (T47Darom) and respective control (T47Dcon) breast cancer cell lines by stable transfection with plasmid containing CYP19A1 gene, or empty vector respectively. Letrozole resistant cell line (T47DaromLR) was generated by incubating T47Darom for 75 weeks in the presence of 10μM Letrozole. Cell proliferation was determined by MTT or crystal violet assays. Gene expressions were quantified by QRT-PCR whereas proteins were identified by western blot analyses, flow cytometry and immunofluorescence staining. Aromatase activity was determined by estradiol ELISA. The effects of Proellex on the anchorage independent growth were measured by soft agar colony formation. Statistical differences between the various groups were determined by Student's ‘t’ test or ANOVA followed by Bonferroni's post hoc test. Results showed that T47Darom and T47DaromLR cell lines had significantly higher aromatase expression (mRNA; 80–90 fold and protein) and as a result exhibited increased aromatization of testosterone to estradiol as compared to T47Dcon. Both these cell lines showed enhanced growth in the presence of Testosterone (50–60%). In T47DaromLR cells increased PR-B and EGFR expression as compared to T47Dcon cells was observed. Proellex and other known aromatase inhibitors (Letrozole, Anastrozole, and Exemestane) inhibited testosterone induced cell proliferation and anchorage independent growth of T47Darom cells. Cell growth inhibition was significantly greater when cells were treated with Proellex alone or in combination with other AIs as compared to AIs alone. Proellex inhibited mRNA and protein levels of PR-B, reduced PRB/p300 complex formation in the nuclei and significantly reduced EGFR expression in T47Darom cells. Our results in the present study indicate that antiprolifera |
doi_str_mv | 10.1016/j.jsbmb.2012.08.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1221859464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960076012001471</els_id><sourcerecordid>1221859464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-afce3d35cb215b57ae01d4fdacc362f571b239ca88b67de6337116d37bfb050d3</originalsourceid><addsrcrecordid>eNp9UctuFDEQtBCILIEvQEI-cmCGtj0znjlwQCE8pJXIITlbfrSDVzvjxfZGCb-Qn443GzgitWTLqqp2VRHylkHLgA0fN-0mm9m0HBhvYWwBumdkxUY5NYxzeE5WMA3QgBzghLzKeQMAQjD5kpxwPolpHOWK3J97H6y2d1Qvjs5of-kl5JlGT7UtIS6H20WKuN3i7YcKqlPCLsVrzCUstI5OcdZFZ6TxBhPe7hLmHJbrR8U1lhT_xC3S-hpyqWx62ckv1CTUuVCrF4uJ2qqfX5MXXm8zvnk6T8nV1_PLs-_N-ue3H2ef143teF8a7S0KJ3prOOtNLzUCc5132loxcN9LZriYrB5HM0iHgxCSscEJabyBHpw4Je-PutXG7331oeaQDz_QC8Z9VjU9NvZTN3QVKo5Qm2LOCb3apTDrdKcYqEMLaqMeW1CHFhSMqrZQWe-eFuzNjO4f52_sFfDpCMBq8yZgUtkGrEm4kNAW5WL474IHbIeccw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221859464</pqid></control><display><type>article</type><title>Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Gupta, Akash ; Mehta, Rajeshwari ; Alimirah, Fatouma ; Peng, Xinjian ; Murillo, Genoveva ; Wiehle, Ronald ; Mehta, Rajendra G.</creator><creatorcontrib>Gupta, Akash ; Mehta, Rajeshwari ; Alimirah, Fatouma ; Peng, Xinjian ; Murillo, Genoveva ; Wiehle, Ronald ; Mehta, Rajendra G.</creatorcontrib><description>► Aromatase overexpressing and Letrozole resistant T47D cell lines were generated. ► Antiprogestin, Proellex, suppressed growth of these cells in vitro. ► Proellex action is mediated by inhibiting PR-B/p300 complex formation. ► Proellex suppresses EGFR and PR-B expression.
Aromatase inhibitors (AI) are considered as a first line therapy for ER+PR+ breast cancers. However, many patients acquire resistance to AI. In this study, we determined the response of antiprogestin CDB-4124 (Proellex) on the aromatase overexpressing and Letrozole resistant cell lines and also studies its mechanism of action in inhibition of breast cancer cell proliferation. For these studies we generated aromatase overexpressing T47D (T47Darom) and respective control (T47Dcon) breast cancer cell lines by stable transfection with plasmid containing CYP19A1 gene, or empty vector respectively. Letrozole resistant cell line (T47DaromLR) was generated by incubating T47Darom for 75 weeks in the presence of 10μM Letrozole. Cell proliferation was determined by MTT or crystal violet assays. Gene expressions were quantified by QRT-PCR whereas proteins were identified by western blot analyses, flow cytometry and immunofluorescence staining. Aromatase activity was determined by estradiol ELISA. The effects of Proellex on the anchorage independent growth were measured by soft agar colony formation. Statistical differences between the various groups were determined by Student's ‘t’ test or ANOVA followed by Bonferroni's post hoc test. Results showed that T47Darom and T47DaromLR cell lines had significantly higher aromatase expression (mRNA; 80–90 fold and protein) and as a result exhibited increased aromatization of testosterone to estradiol as compared to T47Dcon. Both these cell lines showed enhanced growth in the presence of Testosterone (50–60%). In T47DaromLR cells increased PR-B and EGFR expression as compared to T47Dcon cells was observed. Proellex and other known aromatase inhibitors (Letrozole, Anastrozole, and Exemestane) inhibited testosterone induced cell proliferation and anchorage independent growth of T47Darom cells. Cell growth inhibition was significantly greater when cells were treated with Proellex alone or in combination with other AIs as compared to AIs alone. Proellex inhibited mRNA and protein levels of PR-B, reduced PRB/p300 complex formation in the nuclei and significantly reduced EGFR expression in T47Darom cells. Our results in the present study indicate that antiproliferative effect of Proellex is probably due to PR-B/EGFR modulation in ER+PR+, aromatase expressing cells. Overall these results suggest that antiprogestin, Proellex can be developed as a possible treatment strategy for aromatase overexpressing ER+/PR+ breast cancer patients as well as for aromatase inhibitor resistant breast cancer patients.</description><identifier>ISSN: 0960-0760</identifier><identifier>EISSN: 1879-1220</identifier><identifier>DOI: 10.1016/j.jsbmb.2012.08.004</identifier><identifier>PMID: 22939887</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Agents, Hormonal - pharmacology ; Antiprogestin ; Aromatase - genetics ; Aromatase - metabolism ; Aromatase inhibitor ; Aromatase Inhibitors - pharmacology ; Base Sequence ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cell Adhesion ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Drug Resistance, Neoplasm ; Female ; Gene Expression ; Genes, erbB-1 - drug effects ; Humans ; Nitriles - pharmacology ; Norpregnadienes - pharmacology ; Progestins - antagonists & inhibitors ; Promegestone - pharmacology ; Receptors, Progesterone - genetics ; Receptors, Progesterone - metabolism ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; RNA, Neoplasm - genetics ; RNA, Neoplasm - metabolism ; Tamoxifen - pharmacology ; Testosterone - pharmacology ; Triazoles - pharmacology ; Tumor Stem Cell Assay</subject><ispartof>The Journal of steroid biochemistry and molecular biology, 2013-01, Vol.133, p.30-42</ispartof><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-afce3d35cb215b57ae01d4fdacc362f571b239ca88b67de6337116d37bfb050d3</citedby><cites>FETCH-LOGICAL-c425t-afce3d35cb215b57ae01d4fdacc362f571b239ca88b67de6337116d37bfb050d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jsbmb.2012.08.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22939887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Akash</creatorcontrib><creatorcontrib>Mehta, Rajeshwari</creatorcontrib><creatorcontrib>Alimirah, Fatouma</creatorcontrib><creatorcontrib>Peng, Xinjian</creatorcontrib><creatorcontrib>Murillo, Genoveva</creatorcontrib><creatorcontrib>Wiehle, Ronald</creatorcontrib><creatorcontrib>Mehta, Rajendra G.</creatorcontrib><title>Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells</title><title>The Journal of steroid biochemistry and molecular biology</title><addtitle>J Steroid Biochem Mol Biol</addtitle><description>► Aromatase overexpressing and Letrozole resistant T47D cell lines were generated. ► Antiprogestin, Proellex, suppressed growth of these cells in vitro. ► Proellex action is mediated by inhibiting PR-B/p300 complex formation. ► Proellex suppresses EGFR and PR-B expression.
Aromatase inhibitors (AI) are considered as a first line therapy for ER+PR+ breast cancers. However, many patients acquire resistance to AI. In this study, we determined the response of antiprogestin CDB-4124 (Proellex) on the aromatase overexpressing and Letrozole resistant cell lines and also studies its mechanism of action in inhibition of breast cancer cell proliferation. For these studies we generated aromatase overexpressing T47D (T47Darom) and respective control (T47Dcon) breast cancer cell lines by stable transfection with plasmid containing CYP19A1 gene, or empty vector respectively. Letrozole resistant cell line (T47DaromLR) was generated by incubating T47Darom for 75 weeks in the presence of 10μM Letrozole. Cell proliferation was determined by MTT or crystal violet assays. Gene expressions were quantified by QRT-PCR whereas proteins were identified by western blot analyses, flow cytometry and immunofluorescence staining. Aromatase activity was determined by estradiol ELISA. The effects of Proellex on the anchorage independent growth were measured by soft agar colony formation. Statistical differences between the various groups were determined by Student's ‘t’ test or ANOVA followed by Bonferroni's post hoc test. Results showed that T47Darom and T47DaromLR cell lines had significantly higher aromatase expression (mRNA; 80–90 fold and protein) and as a result exhibited increased aromatization of testosterone to estradiol as compared to T47Dcon. Both these cell lines showed enhanced growth in the presence of Testosterone (50–60%). In T47DaromLR cells increased PR-B and EGFR expression as compared to T47Dcon cells was observed. Proellex and other known aromatase inhibitors (Letrozole, Anastrozole, and Exemestane) inhibited testosterone induced cell proliferation and anchorage independent growth of T47Darom cells. Cell growth inhibition was significantly greater when cells were treated with Proellex alone or in combination with other AIs as compared to AIs alone. Proellex inhibited mRNA and protein levels of PR-B, reduced PRB/p300 complex formation in the nuclei and significantly reduced EGFR expression in T47Darom cells. Our results in the present study indicate that antiproliferative effect of Proellex is probably due to PR-B/EGFR modulation in ER+PR+, aromatase expressing cells. Overall these results suggest that antiprogestin, Proellex can be developed as a possible treatment strategy for aromatase overexpressing ER+/PR+ breast cancer patients as well as for aromatase inhibitor resistant breast cancer patients.</description><subject>Antineoplastic Agents, Hormonal - pharmacology</subject><subject>Antiprogestin</subject><subject>Aromatase - genetics</subject><subject>Aromatase - metabolism</subject><subject>Aromatase inhibitor</subject><subject>Aromatase Inhibitors - pharmacology</subject><subject>Base Sequence</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Adhesion</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genes, erbB-1 - drug effects</subject><subject>Humans</subject><subject>Nitriles - pharmacology</subject><subject>Norpregnadienes - pharmacology</subject><subject>Progestins - antagonists & inhibitors</subject><subject>Promegestone - pharmacology</subject><subject>Receptors, Progesterone - genetics</subject><subject>Receptors, Progesterone - metabolism</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>RNA, Neoplasm - genetics</subject><subject>RNA, Neoplasm - metabolism</subject><subject>Tamoxifen - pharmacology</subject><subject>Testosterone - pharmacology</subject><subject>Triazoles - pharmacology</subject><subject>Tumor Stem Cell Assay</subject><issn>0960-0760</issn><issn>1879-1220</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctuFDEQtBCILIEvQEI-cmCGtj0znjlwQCE8pJXIITlbfrSDVzvjxfZGCb-Qn443GzgitWTLqqp2VRHylkHLgA0fN-0mm9m0HBhvYWwBumdkxUY5NYxzeE5WMA3QgBzghLzKeQMAQjD5kpxwPolpHOWK3J97H6y2d1Qvjs5of-kl5JlGT7UtIS6H20WKuN3i7YcKqlPCLsVrzCUstI5OcdZFZ6TxBhPe7hLmHJbrR8U1lhT_xC3S-hpyqWx62ckv1CTUuVCrF4uJ2qqfX5MXXm8zvnk6T8nV1_PLs-_N-ue3H2ef143teF8a7S0KJ3prOOtNLzUCc5132loxcN9LZriYrB5HM0iHgxCSscEJabyBHpw4Je-PutXG7331oeaQDz_QC8Z9VjU9NvZTN3QVKo5Qm2LOCb3apTDrdKcYqEMLaqMeW1CHFhSMqrZQWe-eFuzNjO4f52_sFfDpCMBq8yZgUtkGrEm4kNAW5WL474IHbIeccw</recordid><startdate>201301</startdate><enddate>201301</enddate><creator>Gupta, Akash</creator><creator>Mehta, Rajeshwari</creator><creator>Alimirah, Fatouma</creator><creator>Peng, Xinjian</creator><creator>Murillo, Genoveva</creator><creator>Wiehle, Ronald</creator><creator>Mehta, Rajendra G.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201301</creationdate><title>Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells</title><author>Gupta, Akash ; Mehta, Rajeshwari ; Alimirah, Fatouma ; Peng, Xinjian ; Murillo, Genoveva ; Wiehle, Ronald ; Mehta, Rajendra G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-afce3d35cb215b57ae01d4fdacc362f571b239ca88b67de6337116d37bfb050d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic Agents, Hormonal - pharmacology</topic><topic>Antiprogestin</topic><topic>Aromatase - genetics</topic><topic>Aromatase - metabolism</topic><topic>Aromatase inhibitor</topic><topic>Aromatase Inhibitors - pharmacology</topic><topic>Base Sequence</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Adhesion</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genes, erbB-1 - drug effects</topic><topic>Humans</topic><topic>Nitriles - pharmacology</topic><topic>Norpregnadienes - pharmacology</topic><topic>Progestins - antagonists & inhibitors</topic><topic>Promegestone - pharmacology</topic><topic>Receptors, Progesterone - genetics</topic><topic>Receptors, Progesterone - metabolism</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>RNA, Neoplasm - genetics</topic><topic>RNA, Neoplasm - metabolism</topic><topic>Tamoxifen - pharmacology</topic><topic>Testosterone - pharmacology</topic><topic>Triazoles - pharmacology</topic><topic>Tumor Stem Cell Assay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Akash</creatorcontrib><creatorcontrib>Mehta, Rajeshwari</creatorcontrib><creatorcontrib>Alimirah, Fatouma</creatorcontrib><creatorcontrib>Peng, Xinjian</creatorcontrib><creatorcontrib>Murillo, Genoveva</creatorcontrib><creatorcontrib>Wiehle, Ronald</creatorcontrib><creatorcontrib>Mehta, Rajendra G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of steroid biochemistry and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Akash</au><au>Mehta, Rajeshwari</au><au>Alimirah, Fatouma</au><au>Peng, Xinjian</au><au>Murillo, Genoveva</au><au>Wiehle, Ronald</au><au>Mehta, Rajendra G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells</atitle><jtitle>The Journal of steroid biochemistry and molecular biology</jtitle><addtitle>J Steroid Biochem Mol Biol</addtitle><date>2013-01</date><risdate>2013</risdate><volume>133</volume><spage>30</spage><epage>42</epage><pages>30-42</pages><issn>0960-0760</issn><eissn>1879-1220</eissn><abstract>► Aromatase overexpressing and Letrozole resistant T47D cell lines were generated. ► Antiprogestin, Proellex, suppressed growth of these cells in vitro. ► Proellex action is mediated by inhibiting PR-B/p300 complex formation. ► Proellex suppresses EGFR and PR-B expression.
Aromatase inhibitors (AI) are considered as a first line therapy for ER+PR+ breast cancers. However, many patients acquire resistance to AI. In this study, we determined the response of antiprogestin CDB-4124 (Proellex) on the aromatase overexpressing and Letrozole resistant cell lines and also studies its mechanism of action in inhibition of breast cancer cell proliferation. For these studies we generated aromatase overexpressing T47D (T47Darom) and respective control (T47Dcon) breast cancer cell lines by stable transfection with plasmid containing CYP19A1 gene, or empty vector respectively. Letrozole resistant cell line (T47DaromLR) was generated by incubating T47Darom for 75 weeks in the presence of 10μM Letrozole. Cell proliferation was determined by MTT or crystal violet assays. Gene expressions were quantified by QRT-PCR whereas proteins were identified by western blot analyses, flow cytometry and immunofluorescence staining. Aromatase activity was determined by estradiol ELISA. The effects of Proellex on the anchorage independent growth were measured by soft agar colony formation. Statistical differences between the various groups were determined by Student's ‘t’ test or ANOVA followed by Bonferroni's post hoc test. Results showed that T47Darom and T47DaromLR cell lines had significantly higher aromatase expression (mRNA; 80–90 fold and protein) and as a result exhibited increased aromatization of testosterone to estradiol as compared to T47Dcon. Both these cell lines showed enhanced growth in the presence of Testosterone (50–60%). In T47DaromLR cells increased PR-B and EGFR expression as compared to T47Dcon cells was observed. Proellex and other known aromatase inhibitors (Letrozole, Anastrozole, and Exemestane) inhibited testosterone induced cell proliferation and anchorage independent growth of T47Darom cells. Cell growth inhibition was significantly greater when cells were treated with Proellex alone or in combination with other AIs as compared to AIs alone. Proellex inhibited mRNA and protein levels of PR-B, reduced PRB/p300 complex formation in the nuclei and significantly reduced EGFR expression in T47Darom cells. Our results in the present study indicate that antiproliferative effect of Proellex is probably due to PR-B/EGFR modulation in ER+PR+, aromatase expressing cells. Overall these results suggest that antiprogestin, Proellex can be developed as a possible treatment strategy for aromatase overexpressing ER+/PR+ breast cancer patients as well as for aromatase inhibitor resistant breast cancer patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>22939887</pmid><doi>10.1016/j.jsbmb.2012.08.004</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0960-0760 |
ispartof | The Journal of steroid biochemistry and molecular biology, 2013-01, Vol.133, p.30-42 |
issn | 0960-0760 1879-1220 |
language | eng |
recordid | cdi_proquest_miscellaneous_1221859464 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Antineoplastic Agents, Hormonal - pharmacology Antiprogestin Aromatase - genetics Aromatase - metabolism Aromatase inhibitor Aromatase Inhibitors - pharmacology Base Sequence Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell Adhesion Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm Female Gene Expression Genes, erbB-1 - drug effects Humans Nitriles - pharmacology Norpregnadienes - pharmacology Progestins - antagonists & inhibitors Promegestone - pharmacology Receptors, Progesterone - genetics Receptors, Progesterone - metabolism RNA, Messenger - genetics RNA, Messenger - metabolism RNA, Neoplasm - genetics RNA, Neoplasm - metabolism Tamoxifen - pharmacology Testosterone - pharmacology Triazoles - pharmacology Tumor Stem Cell Assay |
title | Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T08%3A41%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20mechanism%20of%20action%20of%20Proellex,%20an%20antiprogestin%20in%20aromatase%20overexpressing%20and%20Letrozole%20resistant%20T47D%20breast%20cancer%20cells&rft.jtitle=The%20Journal%20of%20steroid%20biochemistry%20and%20molecular%20biology&rft.au=Gupta,%20Akash&rft.date=2013-01&rft.volume=133&rft.spage=30&rft.epage=42&rft.pages=30-42&rft.issn=0960-0760&rft.eissn=1879-1220&rft_id=info:doi/10.1016/j.jsbmb.2012.08.004&rft_dat=%3Cproquest_cross%3E1221859464%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221859464&rft_id=info:pmid/22939887&rft_els_id=S0960076012001471&rfr_iscdi=true |